147 related articles for article (PubMed ID: 9333074)
1. Comparative in vitro activities of trovafloxacin (CP-99,219) against 221 aerobic and 217 anaerobic bacteria isolated from patients with intra-abdominal infections.
Citron DM; Appleman MD
Antimicrob Agents Chemother; 1997 Oct; 41(10):2312-6. PubMed ID: 9333074
[TBL] [Abstract][Full Text] [Related]
2. Comparative in-vitro activities of trovafloxacin, ciproflaxacin, ofloxacin, and broad-spectrum beta-lactams against aerobe blood culture isolates.
Seifert H
Zentralbl Bakteriol; 1998 Dec; 288(4):509-18. PubMed ID: 9987189
[TBL] [Abstract][Full Text] [Related]
3. In vitro activities of trovafloxacin against 557 strains of anaerobic bacteria.
Wexler HM; Molitoris E; Molitoris D; Finegold SM
Antimicrob Agents Chemother; 1996 Sep; 40(9):2232-5. PubMed ID: 8878617
[TBL] [Abstract][Full Text] [Related]
4. In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections.
Edmiston CE; Krepel CJ; Seabrook GR; Somberg LR; Nakeeb A; Cambria RA; Towne JB
Antimicrob Agents Chemother; 2004 Mar; 48(3):1012-6. PubMed ID: 14982797
[TBL] [Abstract][Full Text] [Related]
5. Comparative in vitro activities of trovafloxacin (CP 99,219) and other antimicrobials against clinically significant anaerobes.
Aldridge KE; Ashcraft D; Bowman KA
Antimicrob Agents Chemother; 1997 Feb; 41(2):484-7. PubMed ID: 9021215
[TBL] [Abstract][Full Text] [Related]
6. Comparative in vitro activities of trovafloxacin (CP-99,219) against 445 gram-positive isolates from patients with endocarditis and those with other bloodstream infections.
Endtz HP; Mouton JW; den Hollander JG; van den Braak N; Verbrugh HA
Antimicrob Agents Chemother; 1997 May; 41(5):1146-9. PubMed ID: 9145886
[TBL] [Abstract][Full Text] [Related]
7. The in-vitro activity of tosufloxacin, a new fluorinated quinolone, compared with that of ciprofloxacin and temafloxacin.
King A; Bethune L; Phillips I
J Antimicrob Chemother; 1991 Nov; 28(5):719-25. PubMed ID: 1663930
[TBL] [Abstract][Full Text] [Related]
8. In-vitro activity of clinafloxacin (CI-960) and PD 131628-2 against anaerobic bacteria.
Wexler HM; Molitoris E; Reeves D; Finegold SM
J Antimicrob Chemother; 1994 Oct; 34(4):579-84. PubMed ID: 7868409
[TBL] [Abstract][Full Text] [Related]
9. The in-vitro activity of trovafloxacin and nine other antimicrobials against 413 anaerobic bacteria.
Bowker KE; Wootton M; Holt HA; Reeves DS; MacGowan AP
J Antimicrob Chemother; 1996 Aug; 38(2):271-81. PubMed ID: 8877542
[TBL] [Abstract][Full Text] [Related]
10. Comparative in vitro antimicrobial activity of a novel quinolone, garenoxacin, against aerobic and anaerobic microbial isolates recovered from general, vascular, cardiothoracic and otolaryngologic surgical patients.
Edmiston CE; Krepel CJ; Kehl KS; Seabrook GR; Somberg LB; Almassi GH; Smith TL; Loehrl TA; Brown KR; Lewis BD; Towne JB
J Antimicrob Chemother; 2005 Nov; 56(5):872-8. PubMed ID: 16186167
[TBL] [Abstract][Full Text] [Related]
11. Methods of measuring susceptibility of anaerobic bacteria to trovafloxacin, including quality control parameters.
Barry AL; Fuchs PC; Thornsberry C; McLaughlin JC; Jenkins SG; Hardy DJ; Allen SD
Eur J Clin Microbiol Infect Dis; 1996 Aug; 15(8):676-8. PubMed ID: 8894579
[TBL] [Abstract][Full Text] [Related]
12. In-vitro activity of trovafloxacin against sensitive and resistant aerobic bacteria using the standard microdilution broth method and Etest.
Dembry LM; Farrel PA; Orcutt DR; Gerrity LA; Andriole VT
J Antimicrob Chemother; 1997 Jun; 39 Suppl B():35-42. PubMed ID: 9222068
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of gemifloxacin compared to seven other oral antimicrobial agents against aerobic and anaerobic pathogens isolated from antral sinus puncture specimens from patients with sinusitis.
Goldstein EJ; Conrads G; Citron DM; Merriam CV; Warren Y; Tyrrell K
Diagn Microbiol Infect Dis; 2002 Feb; 42(2):113-8. PubMed ID: 11858906
[TBL] [Abstract][Full Text] [Related]
14. Trovafloxacin compared with levofloxacin, ofloxacin, ciprofloxacin, azithromycin and clarithromycin against unusual aerobic and anaerobic human and animal bite-wound pathogens.
Goldstein EJ; Citron DM; Hudspeth M; Hunt Gerardo S; Merriam CV
J Antimicrob Chemother; 1998 Mar; 41(3):391-6. PubMed ID: 9578167
[TBL] [Abstract][Full Text] [Related]
15. Comparison of activities of trovafloxacin (CP-99,219) and five other agents against 585 anaerobes with use of three media.
Hecht DW; Osmolski JR
Clin Infect Dis; 1996 Dec; 23 Suppl 1():S44-50. PubMed ID: 8953106
[TBL] [Abstract][Full Text] [Related]
16. Trovafloxacin susceptibility of aerobic clinical bacterial isolates from Sweden.
Rylander M; Walder M; Lind-Brandberg L; Larsson P; Törnqvist E; Monsen T; Kronvall G
Scand J Infect Dis; 1999; 31(6):567-72. PubMed ID: 10680987
[TBL] [Abstract][Full Text] [Related]
17. Calibration of the disk diffusion test for trovafloxacin susceptibility testing of four anaerobic species.
Kronvall G; Holst E
Clin Microbiol Infect; 2000 Apr; 6(4):195-201. PubMed ID: 11168107
[TBL] [Abstract][Full Text] [Related]
18. Antibacterial activity of trovafloxacin against nosocomial Gram-positive and Gram-negative isolates.
Cunha BA; Qadri SM; Ueno Y; Walters EA; Domenico P
J Antimicrob Chemother; 1997 Jun; 39 Suppl B():29-34. PubMed ID: 9222067
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of trovafloxacin versus ciprofloxacin against clinical isolates.
Verbist L; Verhaegen J
Eur J Clin Microbiol Infect Dis; 1996 Aug; 15(8):683-5. PubMed ID: 8894581
[TBL] [Abstract][Full Text] [Related]
20. In vitro antibacterial activity of trovafloxacin and five other fluoroquinolones.
Montanari MP; Prenna M; Mingoia M; Ripa S; Varaldo PE
Chemotherapy; 1998; 44(2):85-93. PubMed ID: 9551237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
